{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T10:21:09Z","timestamp":1786357269622,"version":"build-2736575974"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.critrevonc.2025.104699","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T17:34:18Z","timestamp":1742232858000},"page":"104699","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["The impact of urine biomarkers for prostate cancer detection\u2013A systematic state of the art review"],"prefix":"10.1016","volume":"210","author":[{"given":"Stefan","family":"Plas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Melchior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard P.","family":"Aigner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Frantzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Pencik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Kafka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1517-5746","authenticated-orcid":false,"given":"Isabel","family":"Heidegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.104699_bib1","unstructured":"The American Cancer Society medical and editorial content team. Key Statistics for Prostate Cancer | Prostate Cancer Facts 01\/23. \u3008https:\/\/www.cancer.org\/cancer\/types\/prostate-cancer\/about\/key-statistics.html\u3009 (accessed November 14, 2023)."},{"key":"10.1016\/j.critrevonc.2025.104699_bib2","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12916-021-02230-y","article-title":"Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of prostate cancer in symptomatic patients","volume":"20","author":"Merriel","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.critrevonc.2025.104699_bib3","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.euo.2023.12.005","article-title":"Comparing the performance of digital rectal examination and prostate-specific antigen as a screening test for prostate cancer: a systematic review and meta-analysis","volume":"7","author":"Matsukawa","year":"2024","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104699_bib4","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.eururo.2007.02.062","article-title":"Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients","volume":"52","author":"Guichard","year":"2007","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2025.104699_bib5","unstructured":"EAU Guidelines on Prostate Cancer. Edn. presented at the EAU Annual Congress Paris 2024. ISBN 978-94-92671-23-3. European Association of Urology n.d. \u3008https:\/\/uroweb.org\/guidelines\/prostate-cancer\/\u3009 (accessed May 14, 2024)."},{"key":"10.1016\/j.critrevonc.2025.104699_bib6","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/JU.0000000000001399","article-title":"Nonantibiotic Strategies for the Prevention of Infectious Complications following Prostate Biopsy: A Systematic Review and Meta-Analysis","volume":"205","author":"Pradere","year":"2021","journal-title":"J. Urol."},{"key":"10.1016\/j.critrevonc.2025.104699_bib7","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2025.104699_bib8","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.eururo.2018.11.031","article-title":"Detection of individual prostate cancer foci via multiparametric magnetic resonance imaging","volume":"75","author":"Johnson","year":"2019","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2025.104699_bib9","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1148\/radiol.2020190646","article-title":"Variability of the positive predictive value of PI-RADS for prostate MRI across 26 centers: experience of the society of abdominal radiology prostate cancer disease-focused panel","volume":"296","author":"Westphalen","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.critrevonc.2025.104699_bib10","doi-asserted-by":"crossref","DOI":"10.1177\/17562872221103988","article-title":"Biomarkers for prostate cancer detection and risk stratification","volume":"14","author":"Farha","year":"2022","journal-title":"Ther. Adv. Urol."},{"key":"10.1016\/j.critrevonc.2025.104699_bib11","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/s41416-019-0585-4","article-title":"Identification of a biomarker panel for improvement of prostate cancer diagnosis by volatile metabolic profiling of urine","volume":"121","author":"Lima","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104699_bib12","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41391-018-0101-6","article-title":"Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance","volume":"22","author":"Kim","year":"2019","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.critrevonc.2025.104699_bib13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.eururo.2017.09.013","article-title":"A biopsy-based 17-gene genomic prostate score as a predictor of metastases and prostate cancer death in surgically treated men with clinically localized disease","volume":"73","author":"Van Den Eeden","year":"2018","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2025.104699_bib14","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/bjc.2015.223","article-title":"Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort","volume":"113","author":"Cuzick","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104699_bib15","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.juro.2014.04.013","article-title":"Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies","volume":"192","author":"Partin","year":"2014","journal-title":"J. Urol."},{"key":"10.1016\/j.critrevonc.2025.104699_bib16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/bco2.8","article-title":"Development and validation of a novel multivariate risk score to guide biopsy decision for the diagnosis of clinically significant prostate cancer","volume":"1","author":"Klocker","year":"2020","journal-title":"BJUI Compass"},{"key":"10.1016\/j.critrevonc.2025.104699_bib17","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.eururo.2014.10.021","article-title":"A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer","volume":"68","author":"Parekh","year":"2015","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2025.104699_bib18","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.juro.2014.10.121","article-title":"The prostate health index selectively identifies clinically significant prostate cancer","volume":"193","author":"Loeb","year":"2015","journal-title":"J. Urol."},{"key":"10.1016\/j.critrevonc.2025.104699_bib19","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.clgc.2019.02.003","article-title":"Application of urinary volatile organic compounds (VOCs) for the diagnosis of prostate cancer","volume":"17","author":"Gao","year":"2019","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104699_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102195","article-title":"Quantitative investigation of MicroRNA-32 in the urine of prostate cancer patients and its relationship with clinicopathological characteristics","volume":"22","author":"Mahdizade","year":"2024","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104699_bib21","doi-asserted-by":"crossref","first-page":"308","DOI":"10.21873\/cgp.20383","article-title":"Combination of urinary MiR-501 and MiR-335 with current clinical diagnostic parameters as potential predictive factors of prostate biopsy outcome","volume":"20","author":"Juracek","year":"2023","journal-title":"Cancer Genom. Proteom."},{"key":"10.1016\/j.critrevonc.2025.104699_bib22","first-page":"5975","article-title":"DD3: a new prostate-specific gene, highly overexpressed in prostate cancer","volume":"59","author":"Bussemakers","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.104699_bib23","doi-asserted-by":"crossref","first-page":"8403","DOI":"10.1073\/pnas.1507882112","article-title":"PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3","volume":"112","author":"Salameh","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.critrevonc.2025.104699_bib24","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0302-2838(03)00201-X","article-title":"DD3PCA3-based molecular urine analysis for the diagnosis of prostate cancer","volume":"44","author":"Hessels","year":"2003","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2025.104699_bib25","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.juro.2013.02.018","article-title":"PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study","volume":"190","author":"Gittelman","year":"2013","journal-title":"J. Urol."},{"key":"10.1016\/j.critrevonc.2025.104699_bib26","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1126\/science.1117679","article-title":"Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer","volume":"310","author":"Tomlins","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2025.104699_bib27","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nature06024","article-title":"Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer","volume":"448","author":"Tomlins","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2025.104699_bib28","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1158\/1078-0432.CCR-07-5194","article-title":"Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications","volume":"14","author":"Mosquera","year":"2008","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.104699_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001970","article-title":"Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA","volume":"3","author":"Tomlins","year":"2011","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.critrevonc.2025.104699_bib30","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines \u00ae): Prostate Early Detection V2.2024. National Comprehensive Cancer Network n.d. \u3008https:\/\/www.nccn.org\/login?ReturnURL=https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate_detection.pdf\u3009 (accessed August 19, 2024)."},{"key":"10.1016\/j.critrevonc.2025.104699_bib31","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1001\/jamaoncol.2024.0455","article-title":"Development and validation of an 18-gene urine test for high-grade prostate cancer","volume":"10","author":"Tosoian","year":"2024","journal-title":"JAMA Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104699_bib32","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/iju.13734","article-title":"Urinary biomarkers of prostate cancer","volume":"25","author":"Fujita","year":"2018","journal-title":"Int J. Urol."},{"key":"10.1016\/j.critrevonc.2025.104699_bib33","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1074\/jbc.275.2.1216","article-title":"PDEF, a novel prostate epithelium-specific ets transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression","volume":"275","author":"Oettgen","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.critrevonc.2025.104699_bib34","unstructured":"PubChem. SPDEF - SAM pointed domain containing ETS transcription factor (human) n.d. \u3008https:\/\/pubchem.ncbi.nlm.nih.gov\/gene\/SPDEF\/human\u3009 (accessed September 17, 2024)."},{"key":"10.1016\/j.critrevonc.2025.104699_bib35","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/sj.onc.1207906","article-title":"Loss of HOXC6 expression induces apoptosis in prostate cancer cells","volume":"24","author":"Ramachandran","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2025.104699_bib36","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.yexcr.2018.01.007","article-title":"DLX1, a binding protein of beta-catenin, promoted the growth and migration of prostate cancer cells","volume":"363","author":"Liang","year":"2018","journal-title":"Exp. Cell Res"},{"key":"10.1016\/j.critrevonc.2025.104699_bib37","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.eururo.2016.04.012","article-title":"Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score","volume":"70","author":"Van Neste","year":"2016","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2025.104699_bib38","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/JU.0000000000000293","article-title":"Multicenter optimization and validation of a 2-Gene mRNA urine test for detection of clinically significant prostate cancer before initial prostate biopsy","volume":"202","author":"Haese","year":"2019","journal-title":"J. Urol."},{"key":"10.1016\/j.critrevonc.2025.104699_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1261\/rna.068692.118","article-title":"Post-transcriptional control of miRNA biogenesis","volume":"25","author":"Michlewski","year":"2019","journal-title":"RNA"},{"key":"10.1016\/j.critrevonc.2025.104699_bib40","doi-asserted-by":"crossref","first-page":"6653","DOI":"10.1038\/s41598-018-24424-w","article-title":"A plasma biomarker panel of four MicroRNAs for the diagnosis of prostate cancer","volume":"8","author":"Matin","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2025.104699_bib41","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.juro.2017.12.006","article-title":"Assessment of serum microRNA biomarkers to predict reclassification of prostate cancer in patients on active surveillance","volume":"199","author":"Liu","year":"2018","journal-title":"J. Urol."},{"key":"10.1016\/j.critrevonc.2025.104699_bib42","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12967-019-1920-5","article-title":"Circulating miRNAs as non-invasive biomarkers to predict aggressive prostate cancer after radical prostatectomy","volume":"17","author":"Hoey","year":"2019","journal-title":"J. Transl. Med"},{"key":"10.1016\/j.critrevonc.2025.104699_bib43","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3390\/cells8010055","article-title":"The ribosome biogenesis\u2014cancer connection","volume":"8","author":"Penzo","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2025.104699_bib44","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/JU.0000000000001020","article-title":"Expression of small noncoding RNAs in urinary exosomes classifies prostate cancer into indolent and aggressive disease","volume":"204","author":"Wang","year":"2020","journal-title":"J. Urol."},{"key":"10.1016\/j.critrevonc.2025.104699_bib45","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.3390\/cancers15041166","article-title":"Mass spectrometry-based biomarkers to detect prostate cancer: a multicentric study based on non-invasive urine collection without prior digital rectal examination","volume":"15","author":"Frantzi","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2025.104699_bib46","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1038\/s41416-019-0472-z","article-title":"CE\u2013MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer","volume":"120","author":"Frantzi","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104699_bib47","doi-asserted-by":"crossref","first-page":"5662","DOI":"10.4049\/jimmunol.180.8.5662","article-title":"A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation","volume":"180","author":"Gaggar","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104699_bib48","unstructured":"miR SentinelTM Prostate Cancer Test n.d \u3008https:\/\/www.mirsentinel.com\/\u3009 (accessed November 13, 2024)."},{"key":"10.1016\/j.critrevonc.2025.104699_bib49","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1007\/s00345-022-04077-1","article-title":"Validation of diagnostic nomograms based on CE\u2013MS urinary biomarkers to detect clinically significant prostate cancer","volume":"40","author":"Frantzi","year":"2022","journal-title":"World J. Urol."},{"key":"10.1016\/j.critrevonc.2025.104699_bib50","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2025.104699_bib51","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann. Intern Med"},{"key":"10.1016\/j.critrevonc.2025.104699_bib52","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1038\/s41598-022-08608-z","article-title":"Validation of a CE-IVD, urine exosomal RNA expression assay for risk assessment of prostate cancer prior to biopsy","volume":"12","author":"Kretschmer","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2025.104699_bib53","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/pcan.2015.40","article-title":"A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result","volume":"18","author":"Donovan","year":"2015","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.critrevonc.2025.104699_bib54","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.eururo.2018.08.019","article-title":"A prospective adaptive utility trial to validate performance of a novel urine exosome gene expression assay to predict high-grade prostate cancer in patients with prostate-specific antigen 2-10ng\/mL at initial biopsy","volume":"74","author":"McKiernan","year":"2018","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2025.104699_bib55","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/s41391-023-00675-1","article-title":"ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer - an interim analysis","volume":"26","author":"Tutrone","year":"2023","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.critrevonc.2025.104699_bib56","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1001\/jamaoncol.2016.0097","article-title":"A novel urine exosome gene expression assay to predict high-grade prostate cancer at initial biopsy","volume":"2","author":"McKiernan","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2025.104699_bib57","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.urology.2021.11.033","article-title":"Urinary MyProstateScore (MPS) to rule out clinically-significant cancer in men with equivocal (PI-RADS 3) multiparametric MRI: addressing an unmet clinical need","volume":"164","author":"Tosoian","year":"2022","journal-title":"Urology"},{"key":"10.1016\/j.critrevonc.2025.104699_bib58","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1097\/JU.0000000000001430","article-title":"Use of the MyProstateScore test to rule out clinically significant cancer: validation of a straightforward clinical testing approach","volume":"205","author":"Tosoian","year":"2021","journal-title":"J. Urol."},{"key":"10.1016\/j.critrevonc.2025.104699_bib59","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.eururo.2015.04.039","article-title":"Urine TMPRSS2:ERG plus PCA3 for individualized prostate cancer risk assessment","volume":"70","author":"Tomlins","year":"2016","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2025.104699_bib60","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41391-022-00633-3","article-title":"MyProstateScore in men considering repeat biopsy: validation of a simple testing approach","volume":"26","author":"Tosoian","year":"2023","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.critrevonc.2025.104699_bib61","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/s41391-021-00367-8","article-title":"Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-na\u00efve men","volume":"24","author":"Hendriks","year":"2021","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.critrevonc.2025.104699_bib62","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1007\/s00345-020-03359-w","article-title":"Prospective assessment of two-gene urinary test with multiparametric magnetic resonance imaging of the prostate for men undergoing primary prostate biopsy","volume":"39","author":"Busetto","year":"2021","journal-title":"World J. Urol."},{"key":"10.1016\/j.critrevonc.2025.104699_bib63","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/pros.24182","article-title":"Prospective study of diagnostic accuracy in the detection of high-grade prostate cancer in biopsy-na\u00efve patients with clinical suspicion of prostate cancer who underwent the Select MDx test","volume":"81","author":"Lend\u00ednez-Cano","year":"2021","journal-title":"Prostate"},{"key":"10.1016\/j.critrevonc.2025.104699_bib64","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/pros.23401","article-title":"A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection","volume":"77","author":"Hendriks","year":"2017","journal-title":"Prostate"},{"key":"10.1016\/j.critrevonc.2025.104699_bib65","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/pros.23964","article-title":"Validation of a 2-gene mRNA urine test for the detection of \u2265GG2 prostate cancer in an opportunistic screening population","volume":"80","author":"Rubio-Briones","year":"2020","journal-title":"Prostate"},{"key":"10.1016\/j.critrevonc.2025.104699_bib66","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3390\/cancers12020285","article-title":"Independent evaluation of the respective predictive values for high-grade prostate cancer of clinical information and RNA biomarkers after upfront MRI and image-guided biopsies","volume":"12","author":"Roumigui\u00e9","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2025.104699_bib67","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1200\/JCO.2013.52.8505","article-title":"Can urinary PCA3 supplement PSA in the early detection of prostate cancer?","volume":"32","author":"Wei","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104699_bib68","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1111\/j.1464-410X.2012.11146.x","article-title":"Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy","volume":"110","author":"Sciarra","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.critrevonc.2025.104699_bib69","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.acuro.2016.10.008","article-title":"PCA3 as a second-line biomarker in a prospective controlled randomized opportunistic prostate cancer screening programme","volume":"41","author":"Rubio-Briones","year":"2017","journal-title":"Actas Urol. Esp."},{"key":"10.1016\/j.critrevonc.2025.104699_bib70","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.urology.2016.08.022","article-title":"Risk stratification by urinary prostate cancer gene 3 testing before magnetic resonance imaging-ultrasound fusion-targeted prostate biopsy among men with no history of biopsy","volume":"99","author":"Fenstermaker","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.critrevonc.2025.104699_bib71","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1590\/S1677-5538.IBJU.2015.0155","article-title":"Evaluation of PCA3 and multiparametric MRI\u2019s: collective benefits before deciding initial prostate biopsy for patients with PSA level between 3 and 10ng\/mL","volume":"42","author":"Okcelik","year":"2016","journal-title":"Int Braz. J. Urol."},{"key":"10.1016\/j.critrevonc.2025.104699_bib72","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00345-015-1655-8","article-title":"Prostate cancer gene 3 (PCA3) is of additional predictive value in patients with PI-RADS grade III (intermediate) lesions in the MR-guided re-biopsy setting for prostate cancer","volume":"34","author":"Kaufmann","year":"2016","journal-title":"World J. Urol."},{"key":"10.1016\/j.critrevonc.2025.104699_bib73","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/pros.22898","article-title":"Accuracy of the prostate health index versus the urinary prostate cancer antigen 3 score to predict overall and significant prostate cancer at initial biopsy","volume":"75","author":"Seisen","year":"2015","journal-title":"Prostate"},{"key":"10.1016\/j.critrevonc.2025.104699_bib74","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00345-014-1251-3","article-title":"Additional value of PCA3 density to predict initial prostate biopsy outcome","volume":"32","author":"Ruffion","year":"2014","journal-title":"World J. Urol."},{"key":"10.1016\/j.critrevonc.2025.104699_bib75","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.juro.2013.12.005","article-title":"Urinary PCA3 as a predictor of prostate cancer in a cohort of 3,073 men undergoing initial prostate biopsy","volume":"191","author":"Chevli","year":"2014","journal-title":"J. Urol."},{"key":"10.1016\/j.critrevonc.2025.104699_bib76","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.urology.2014.05.067","article-title":"Reflex PCA3 messenger ribonucleic acid testing: validation of postbiopsy urine samples and correlation with prostate biopsy findings in \u223c2000 patients","volume":"84","author":"Brown","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.critrevonc.2025.104699_bib77","first-page":"553","article-title":"Predicting prostate biopsy outcome using a PCA3-based nomogram in a Polish cohort","volume":"33","author":"Salagierski","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1016\/j.critrevonc.2025.104699_bib78","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/pros.22538","article-title":"Use of PCA3 in detecting prostate cancer in initial and repeat prostate biopsy patients","volume":"73","author":"Goode","year":"2013","journal-title":"Prostate"},{"key":"10.1016\/j.critrevonc.2025.104699_bib79","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.urolonc.2012.05.002","article-title":"PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and\/or suspicious digital rectal examination. First Latin American experience","volume":"31","author":"Ramos","year":"2013","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104699_bib80","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.urology.2013.06.078","article-title":"Prostate cancer gene 3 and multiparametric magnetic resonance can reduce unnecessary biopsies: decision curve analysis to evaluate predictive models","volume":"82","author":"Busetto","year":"2013","journal-title":"Urology"},{"key":"10.1016\/j.critrevonc.2025.104699_bib81","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1442-2042.2010.02711.x","article-title":"Prostate cancer gene 3 urine assay for prostate cancer in Japanese men undergoing prostate biopsy","volume":"18","author":"Ochiai","year":"2011","journal-title":"Int J. Urol."},{"key":"10.1016\/j.critrevonc.2025.104699_bib82","first-page":"1399","article-title":"PCA3 urinary test versus 1H-MRSI and DCEMR in the detection of prostate cancer foci in patients with biochemical alterations","volume":"31","author":"Panebianco","year":"2011","journal-title":"Anticancer Res"},{"key":"10.1016\/j.critrevonc.2025.104699_bib83","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1111\/j.1464-410X.2011.10202.x","article-title":"The role of the PCA3 assay in predicting prostate biopsy outcome in a South African setting","volume":"108","author":"Adam","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.critrevonc.2025.104699_bib84","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3109\/00365599.2010.521187","article-title":"PCA3 as a diagnostic marker for prostate cancer: a validation study on a Swedish patient population","volume":"44","author":"Nyberg","year":"2010","journal-title":"Scand. J. Urol. Nephrol."},{"key":"10.1016\/j.critrevonc.2025.104699_bib85","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/j.juro.2010.06.098","article-title":"PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial","volume":"184","author":"Aubin","year":"2010","journal-title":"J. Urol."},{"key":"10.1016\/j.critrevonc.2025.104699_bib86","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000314078","article-title":"Interpretation of the prostate cancer gene 3 in reference to the individual clinical background: implications for daily practice","volume":"85","author":"Schilling","year":"2010","journal-title":"Urol. Int"},{"key":"10.1016\/j.critrevonc.2025.104699_bib87","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1002\/cncr.24447","article-title":"Rational approach to implementation of prostate cancer antigen 3 into clinical care","volume":"115","author":"Wang","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2025.104699_bib88","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.juro.2007.11.038","article-title":"PCA3: a molecular urine assay for predicting prostate biopsy outcome","volume":"179","author":"Deras","year":"2008","journal-title":"J. Urol."},{"key":"10.1016\/j.critrevonc.2025.104699_bib89","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.urology.2006.12.014","article-title":"PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy","volume":"69","author":"Marks","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.critrevonc.2025.104699_bib90","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.eururo.2012.11.014","article-title":"Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer","volume":"65","author":"Leyten","year":"2014","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2025.104699_bib91","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/jamaoncol.2017.0177","article-title":"Association between combined TMPRSS2:ERG and PCA3 RNA urinary testing and detection of aggressive prostate cancer","volume":"3","author":"Sanda","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2025.104699_bib92","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1515\/cclm-2015-0599","article-title":"Comparative analysis of prostate cancer specific biomarkers PCA3 and ERG in whole urine, urinary sediments and exosomes","volume":"54","author":"Hendriks","year":"2016","journal-title":"Clin. Chem. Lab Med"},{"key":"10.1016\/j.critrevonc.2025.104699_bib93","author":"Frantzi","year":"2024","journal-title":"Valid. a Urin. - Based Proteom. Test. Predict Clin. Signif. Prostate Cancer.: Complement. MRI Pathw."},{"key":"10.1016\/j.critrevonc.2025.104699_bib94","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41391-022-00538-1","article-title":"Accuracy of SelectMDx compared to mpMRI in the diagnosis of prostate cancer: a systematic review and diagnostic meta-analysis","volume":"25","author":"Sari Motlagh","year":"2022","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.critrevonc.2025.104699_bib95","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.euo.2023.10.029","article-title":"Diagnostic accuracy of liquid biomarkers for clinically significant prostate cancer detection: a systematic review and diagnostic meta-analysis of multiple thresholds","volume":"7","author":"Kawada","year":"2024","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104699_bib96","doi-asserted-by":"crossref","DOI":"10.3310\/hta19870","article-title":"The clinical effectiveness and cost-effectiveness of the PROGENSA\u00ae prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation","author":"Nicholson","year":"2015","journal-title":"Health Technol. Assess."},{"issue":"24","key":"10.1016\/j.critrevonc.2025.104699_bib97","first-page":"00144","article-title":"Prediction of clinically significant prostate cancer by a specific collagen-related transcriptome, proteome, and urinome signature","volume":"S2588-9311","author":"Heidegger","year":"2024","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104699_bib98","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.7131","article-title":"Biomarker vs MRI-enhanced strategies for prostate cancer screening","volume":"7","author":"Bj\u00f6rnebo","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.critrevonc.2025.104699_bib99","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-68026-1","article-title":"Urine biomarkers can predict prostate cancer and PI-RADS score prior to biopsy","volume":"14","author":"Pavlovic","year":"2024","journal-title":"Sci. Rep."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825000873?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825000873?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T05:06:05Z","timestamp":1746767165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825000873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":99,"alternative-id":["S1040842825000873"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104699","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of urine biomarkers for prostate cancer detection\u2013A systematic state of the art review","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104699","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104699"}}